However, tumor stage had no effect on the sensitivity, specificity, or overall accuracy in the HE4 group, indicating that HE4 is a suitable biomarker for the early diagnosis of NSCLC (Table 3). This evidence concerns the gene WFDC2 and non-small cell lung carcinoma.